CVE:AQS Aequus Pharmaceuticals (AQS) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free AQS Stock Alerts C$0.02 +0.01 (+33.33%) (As of 05/10/2024 05:43 PM ET) Add Compare Share Share Today's RangeC$0.02▼C$0.0250-Day RangeC$0.01▼C$0.0252-Week RangeC$0.01▼C$0.06Volume246,000 shsAverage Volume199,228 shsMarket CapitalizationC$2.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get Aequus Pharmaceuticals alerts: Email Address Ad Huge AlertsThis 1 Biotech Stock has been shocking the marketsSave the Date: BioStem's 2024 Q1 Call Coming Up!Sign Up for the Live Broadcast here About Aequus Pharmaceuticals Stock (CVE:AQS)Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.Read More AQS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AQS Stock News HeadlinesMay 2, 2024 | finance.yahoo.comAequus Pharmaceuticals Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)April 20, 2024 | seekingalpha.comAQS:CA Aequus Pharmaceuticals Inc.May 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.February 23, 2024 | theglobeandmail.comZoomd Technologies: Top 10 Undervalued Growth Stocks on TSX-V (ZOMD)February 18, 2024 | theglobeandmail.comAequus Pharmaceuticals: Top 10 Undervalued Drug Manufacturers Industry Stocks (AQS)December 12, 2023 | morningstar.comAequus Pharmaceuticals Inc AQSNovember 30, 2023 | msn.comAequus Pharmaceuticals reports Q3 resultsOctober 18, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc up on Thursday (AQS)May 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.October 7, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Thursday (AQS)October 5, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Tuesday (AQS)September 29, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Friday (AQS)September 29, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc flat on Wednesday (AQS)August 30, 2023 | finanznachrichten.deAequus Pharmaceuticals: Aequus Reports Second Quarter 2023 Financial Highlights and General UpdateAugust 29, 2023 | markets.businessinsider.comAequus Reports Second Quarter 2023 Financial Highlights and General UpdateAugust 25, 2023 | theglobeandmail.comClosing Bell: Aequus Pharmaceuticals Inc up on Wednesday (AQS)August 24, 2023 | finance.yahoo.comAequus Announces Zimed PF Now Available in CanadaAugust 22, 2023 | finance.yahoo.comAequus Announces Zimed PF Website LaunchAugust 18, 2023 | finance.yahoo.comAequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in CanadaJuly 6, 2023 | benzinga.comAequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)June 7, 2023 | ca.finance.yahoo.comAQS.V - Aequus Pharmaceuticals Inc.May 31, 2023 | finanznachrichten.deAequus Pharmaceuticals: Aequus Provides General Update and First Quarter 2023 Financial HighlightsMay 31, 2023 | finance.yahoo.comAequus Provides General Update and First Quarter 2023 Financial HighlightsMay 2, 2023 | finance.yahoo.comAequus Provides General Update and Fiscal 2022 Financial ResultsApril 19, 2023 | finance.yahoo.comAequus Grants Stock OptionsApril 5, 2023 | finance.yahoo.comAequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board UpdateMarch 26, 2023 | finance.yahoo.comAequus Pharmaceuticals Inc. (AQS.V)See More Headlines Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/12/2024Next Earnings (Estimated)9/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:AQS CUSIPN/A CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-3,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,569.60% Return on Assets-83.91% Debt Debt-to-Equity Ratio138.88 Current Ratio0.12 Quick Ratio0.46 Sales & Book Value Annual SalesC$1.17 million Price / Sales2.27 Cash FlowC$0.00 per share Price / Cash Flow5.00 Book ValueC($0.03) per share Price / Book-0.67Miscellaneous Outstanding Shares132,630,000Free FloatN/AMarket CapC$2.65 million OptionableNot Optionable Beta0.29 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Douglas Glen Janzen (Age 55)Chairman, CEO & President Comp: $206.25kMs. Ann Fehr CGA (Age 55)CPA, CFO & Corporate Secretary Comp: $136.13kMr. Grant LarsenChief Commercial OfficerKey CompetitorsRadient TechnologiesCVE:RTIAcerus PharmaceuticalsTSE:ASPEntourage HealthCVE:ENTGNeutriSci InternationalCVE:NUSugarBud Craft GrowersCVE:SUGRView All Competitors AQS Stock Analysis - Frequently Asked Questions How have AQS shares performed in 2024? Aequus Pharmaceuticals' stock was trading at C$0.03 at the beginning of 2024. Since then, AQS stock has decreased by 20.0% and is now trading at C$0.02. View the best growth stocks for 2024 here. When is Aequus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our AQS earnings forecast. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF). How do I buy shares of Aequus Pharmaceuticals? Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:AQS) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTrump is sounding the alarmPreserve GoldBill Clinton Backing Biden Replacement???The Freeport SocietyThis 1 Biotech Stock has been shocking the marketsHuge AlertsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.